Search research articles
Contact Us
Filters
Showing results (581-590 of 674) with videos related to
Page
of 68
Sort By:
Cancers
|
December 10, 2021
GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models
Anke Brüning-Richardson, Gary C Shaw, Daniel Tams, et al.
Molecular Cancer Therapeutics
|
March 29, 2011
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family
Sandra R Brave, Kirsty Ratcliffe, Zena Wilson, et al.
Oncogene
|
October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Cancers
|
August 12, 2022
Correction: Brüning-Richardson et al. GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. <i>Cancers</i> 2021, <i>13</i>, 5939
Anke Brüning-Richardson, Gary C Shaw, Daniel Tams, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 11, 2024
Investigating brain dynamics and their association with cognitive control in opioid use disorder using naturalistic and drug cue paradigms
Jean Ye, Saloni Mehta, Hannah Peterson, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Expert opinion on burning questions in cancer myeloid cell biology
Jennifer L Guerriero, Miriam Merad, Florent Ginhoux, et al.
JAMA Dermatology
|
October 13, 2021
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
Kristina M Harris, Dawn E Smilek, Margie Byron, et al.
NPJ Breast Cancer
|
August 18, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Page
of 68
Search research articles
Search
Showing results (581-590 of 674) with videos related to
Sort By:
Page
of 68
Cancers
|
December 10, 2021
GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models
Anke Brüning-Richardson, Gary C Shaw, Daniel Tams, et al.
Molecular Cancer Therapeutics
|
March 29, 2011
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family
Sandra R Brave, Kirsty Ratcliffe, Zena Wilson, et al.
Oncogene
|
October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Cancers
|
August 12, 2022
Correction: Brüning-Richardson et al. GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. <i>Cancers</i> 2021, <i>13</i>, 5939
Anke Brüning-Richardson, Gary C Shaw, Daniel Tams, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 11, 2024
Investigating brain dynamics and their association with cognitive control in opioid use disorder using naturalistic and drug cue paradigms
Jean Ye, Saloni Mehta, Hannah Peterson, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Expert opinion on burning questions in cancer myeloid cell biology
Jennifer L Guerriero, Miriam Merad, Florent Ginhoux, et al.
JAMA Dermatology
|
October 13, 2021
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
Kristina M Harris, Dawn E Smilek, Margie Byron, et al.
NPJ Breast Cancer
|
August 18, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Page
of 68